Compare Adaptive Biotechnologies Corp (ADPT) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Charter Communications Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Charter Communications Inc trades at $133.51 (market cap $16.97B). The key difference: Charter Communications Inc is far larger — about 5.1× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | CHTR | |
|---|---|---|
Market Cap | $3.33B | $16.97B |
Sector | Health | Media |
52-Week High | $22.37 | $411.66 |
52-Week Low | $10.24 | $125.54 |
Enterprise Value | $3.19B | $113.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Charter Communications (CHTR) trades at $138.02, up 0.6% on the day, with a bearish technical signal but deeply discounted valuation metrics including a P/E of 3.66 and EV/EBITDA of 5.32. Recent news highlights a potential mobile partnership with SpaceX, driving significant pre-market gains, while financials show stable revenue near $54.8B and improving operating cash flow to $16.08B in 2025.
The stock presents a high-risk, high-reward opportunity, with a consensus price target of $214 suggesting 55% upside, but faces headwinds from high debt, competitive pressures, and inconsistent earnings beats. Investor sentiment is mixed, balancing low valuation against operational challenges and leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
